Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

N. Girard; J. Bar; P. Baas; C. Chouaid; D.C. Christoph; J.K. Field; R. Fietkau; M.C. Garassino; P. Garrido Lopez; V. Gregorc; V.D. Haakensen; T.J.N. Hiltermann; S. Kao; F. McDonald; F. Mornex; M. Moskovitz; S. Peters; S. Siva; B. Solomon; Y. Qiao; S. Anand; P. Chander; T. Shcherbakova; I. Diaz Perez; A.R. Filippi

doi:10.1016/j.esmoop.2026.106070

Key Points

To evaluate the long-term outcomes of durvalumab following chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.
Analysis of mature data from the PACIFIC-R cohort
Focus on overall survival (OS) and real-world progression-free survival (rwPFS)
Assessment of durvalumab as a consolidation therapy
Durvalumab shows improved overall survival in the cohort
Real-world progression-free survival supports effective treatment outcomes
Findings advocate for durvalumab as standard of care in this patient population

Implication

PACIFIC-R reports improved overall survival and real-world progression-free survival with durvalumab in unresectable NSCLC, highlighting its standard use after treatment.

Abstract

PACIFIC-R provides mature data on OS and rwPFS from a large, real-world cohort, supporting consolidation durvalumab as a standard of care in this setting.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Girard et al. (2026) studied this question.

synapsesocial.com/papers/6988270a0fc35cd7a8845eb6 https://doi.org/10.1016/j.esmoop.2026.106070

View Full Paper

Ask AI

Bookmark

Share

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

Key Points

Implication

Abstract

Discussion

Cite This Study

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading